Lv5
810 积分 2022-12-08 加入
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)
7小时前
待确认
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial
10小时前
待确认
Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial
10小时前
待确认
Migraine
2天前
已完结
Synthesis of substituted cyclodextrins
7天前
已完结
Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study
7天前
已完结
Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicenter retrospective study
9天前
已完结
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
12天前
已完结
Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke
12天前
已完结
Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke
12天前
已完结
皖公网安备34019202002308
